top of page
Search

A 10-Part Series on ISPOR’s Top HEOR Trends: #2 Drug pricing

  • jgao177
  • 4 days ago
  • 2 min read

Drug Pricing ranks as the #2 trend shaping healthcare decision-making in the ISPOR 2024/25 HEOR trend report (https://www.ispor.org/heor-resources/top-10-heor-trends). The report notes the accelerating pricing reform across countries, driven by affordability pressures, rising healthcare costs, and the political momentum behind legislation like the U.S. Inflation Reduction Act (IRA).


The report also highlights value-based pricing frameworks, which are now being implemented in practice. There’s growing attention among policymakers for:

  • Greater pricing transparency

  • Stronger links between price and demonstrated value

  • International reference pricing and collaboration on HTA

  • Real-world evidence and outcome-based arrangements to justify or adjust prices

 

ree

Real-World Examples

United States: The IRA empowers Medicare to negotiate drug prices starting in 2026. The first 10 drugs targeted include high-use, high-spend therapies like Eliquis, Jardiance, and Imbruvica.

European Union: The upcoming Joint Clinical Assessment (EU-JCA) process creates more unified evaluations across member states, streamlining value assessments and reinforcing pressure to justify prices.

Reassessments (Netherlands): Drugs like PARP inhibitors, once approved, are being re-evaluated post-launch to see if real-world evidence supports continued reimbursement.

 

What This Means

Pricing is now about outcomes and system value. Manufacturers need to bring stronger evidence, flexible pricing models, and payer-aligned strategies.Global pricing decisions are interlinked, with one region’s policy influencing others.

Whether it’s outcome-based contracting, indication-specific pricing, or lifecycle re-pricing, the drug pricing conversation is evolving fast and manufacturers must evolve with it.

 

How Evimed Can Help

At Evimed, we help pharma and biotech companies adapt to these shifts through:

·       Global-to-local pricing strategies tailored to payer expectations

·       Design outcome-based and value-based pricing models

·       Evidence generation and communication support to articulate value and justify price

·       Cross-market insight into pricing trends across the U.S., Europe, and Asia


We combine HEOR expertise with strategic thinking to ensure our clients don’t just react to pricing pressure—they anticipate and lead through it.



 
 
 
bottom of page